Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Asset acquisition financial royalty assets Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets Ohtuvayre Intangible Ohtuvayre [Member] Intangible Ohtuvayre Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Reported Value Measurement Reported Value Measurement [Member] Sato Sato [Member] Sato Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] Financial Royalty Assets, net Financial Royalty Assets [Text Block] Financial Royalty Assets Payment for contingent consideration liability, investing activities Payment for Contingent Consideration Liability, Investing Activities Compensation Employee-related Liabilities, Current Orchestra Warrant Orchestra Warrant [Member] Orchestra Warrant Derivative Instrument [Axis] Derivative Instrument [Axis] Convertible Note Hedge and Warrant Convertible Note Hedge and Warrant [Member] Convertible Note Hedge and Warrant Securities called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Debt instrument, convertible, conversion price Debt Instrument, Convertible, Conversion Price Agenus Bot/Bal Agenus, Inc. [Member] Agenus, Inc. Shares acquired, average cost per share Shares Acquired, Average Cost Per Share Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Value-added tax Value Added Tax Receivable Net, Current Value Added Tax Receivable Net, Current Lease amortization expense Finance Lease And Operating Lease, Right-of-Use Asset, Amortization Finance Lease And Operating Lease, Right-of-Use Asset, Amortization Orchestra BioMed Orchestra BioMed [Member] Orchestra BioMed Unrealized losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Asset Acquisition [Axis] Asset Acquisition [Axis] Intangible assets, net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Nonvested at beginning of period (in shares) Nonvested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Accretion of short-term investments Accretion (Amortization) of Discounts and Premiums, Investments Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Convertible Senior Notes due 2030 - Initial Purchase Option Convertible Senior Notes due 2030 - Initial Purchase Option [Member] Convertible Senior Notes due 2030 - Initial Purchase Option Notes Receivable Notes Receivable [Member] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Arecor Warrant Arecor Warrant [Member] Arecor Warrant Customer relationships Customer Relationships [Member] Schedule of Derivative Assets Schedule of Derivative Assets at Fair Value [Table Text Block] Entity Address, City or Town Entity Address, City or Town Contingent liabilities Business Combination, Contingent Consideration, Liability, Fair Value Disclosure Business Combination, Contingent Consideration, Liability, Fair Value Disclosure Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Total definite lived intangible assets Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Elutia (CorMatrix) Elutia And CorMatrix [Member] Elutia And CorMatrix LeonaBio Series A Warrant LeonaBio Series A Warrant [Member] LeonaBio Series A Warrant Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Basis of Presentation Basis of Presentation [Line Items] Basis of presentation. Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Use of Estimates Use of Estimates, Policy [Policy Text Block] Related Party [Axis] Related and Nonrelated Parties [Axis] Shares available for future purchases (in shares) Share-Based Payment Arrangement, Shares Expected to be Repurchased, Next Fiscal Period Schedule of Reconciliation of Level 3 Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Net proceeds from debt issuance Proceeds from Debt, Net of Issuance Costs Credit losses related to available-for-sale debt securities Debt Securities, Available-for-Sale, Allowance for Credit Loss, Writeoff Document Period End Date Document Period End Date Preferred stock outstanding (in shares) Preferred Stock, Shares Outstanding Debt instrument, principal amount Debt Instrument, Face Amount Debt instrument term Debt Instrument, Term Arecor Warrant Agenus Warrants [Member] Agenus Warrants Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Short-term portion of financial royalty assets, net Financial Royalty Assets, Current Financial Royalty Assets, Current Fair Value Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Fair value adjustments to contingent liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Current operating lease liabilities Operating Lease, Liability, Current APEIRON APEIRON [Member] APEIRON Earnings per share Earnings Per Share [Abstract] Financial royalty assets, measurement input (percent) Financial Royalty Asset, Measurement Input Financial Royalty Asset, Measurement Input Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period Total liabilities Liabilities Trading Symbol Trading Symbol Discount Rate Measurement Input, Discount Rate [Member] Summary of Goodwill and Other Identifiable Intangible Assets Intangible Asset, Including Goodwill, after Accumulated Amortization [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Income Tax Disclosure [Abstract] Series A Warrants Series A Warrants [Member] Series A Warrants Other commitment, investment amount, maximum Other Commitment, Investment Amount, Maximum Other Commitment, Investment Amount, Maximum Financial royalty assets, fair value disclosure Financial Royalty Assets, Fair Value Disclosure Financial Royalty Assets, Fair Value Disclosure Credit Facility [Domain] Credit Facility [Domain] Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Acquisition of financial royalty assets Payments To Acquire Financial Royalty Assets Payments To Acquire Financial Royalty Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Line of Credit Facility [Table] Line of Credit Facility [Table] U.S. Treasuries US Treasury Securities [Member] Equity securities in Primrose Bio Primrose Bio [Member] Primrose Bio Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Other assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Share purchase price as percent of market price (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date Fair Value Option, Other Eligible Items Fair Value Option, Other Eligible Items [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Contingent value rights Business Acquisition, Contingent Value Rights Issued Business Acquisition, Contingent Value Rights Issued Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Noncurrent derivative assets Total noncurrent derivative assets Derivative Asset, Noncurrent Effective income tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Primrose mRNA Primrose mRNA [Member] Primrose mRNA Debt instrument, convertible, conversion ratio Debt Instrument, Convertible, Conversion Ratio Dilutive potential common shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Summary of Investment Holdings Summary of Investment Holdings [Line Items] LeonaBio Warrants (noncurrent) LeonaBio Warrants [Member] LeonaBio Warrants Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Fair value of convertible senior notes outstanding (Level 2) Long-Term Debt, Fair Value Investment amount, at closing Other Commitment, Investment Amount, Current Other Commitment, Investment Amount, Current Vaxneuvance Vaxneuvance [Member] Vaxneuvance Depreciation of property and equipment Depreciation Plan Name [Domain] Plan Name [Domain] Allowance Financial Royalty Assets, Allowance Financial Royalty Assets, Allowance Antidilutive Securities [Axis] Antidilutive Securities [Axis] Balance at beginning of period (in USD per share) Balance at end of period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Right-of-use assets Operating Lease, Right-of-Use Asset Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Royalties Royalties Royalty [Member] Product royalty rate Product Royalty Rate Product Royalty Rate Expiration Date Trading Arrangement Expiration Date Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan [Member] Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan Asset acquisition, deferred consideration payable Asset Acquisition, Deferred Consideration Payable Asset Acquisition, Deferred Consideration Payable Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Recognized research and development expense Payments To Acquire Financial Royalty Assets And Recognized Research And Development Expense Payments To Acquire Financial Royalty Assets And Recognized Research And Development Expense Royalty income rate, upper tier (as percent) Royalty Income Rate, Upper Tier Royalty Income Rate, Upper Tier Others Others [Member] Others Disposal Group, Including Discontinued Operations Disposal Group, Including Discontinued Operations [Line Items] Outstanding options that are exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Derivative [Table] Derivative [Table] Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Segments [Domain] Segments [Domain] Debt Debt Disclosure [Text Block] Debt issuance costs, net Debt Issuance Costs, Net Schedule of Financial Royalty Assets Schedule of Financial Royalty Assets [Table Text Block] Schedule of Financial Royalty Assets PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Loan receivable, conversion price Loan Receivable, Conversion Price Loan Receivable, Conversion Price Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Total stockholders’ equity Balance at beginning of period Balance at end of period Equity, Attributable to Parent ASSETS Assets [Abstract] Contractual relationships Contractual Rights [Member] Other investments Total other investments Fair value on December 31, 2025 Fair value on June 30, 2026 Other Investments Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Goodwill and intangible asset impairment Intangible Asset, Including Goodwill, Impairment Loss Insider Trading Policies and Procedures [Line Items] Royalty Rights Royalty Rights [Member] Royalty Rights Performance Shares Performance Shares [Member] Business Business Spin-Off And Migration [Policy Text Block] Business Spin-Off And Migration Other Investments Other Investments Policy [Policy Text Block] Other Investments Policy Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Annual royalty payment Annual Royalty Fee Annual Royalty Fee Private Placement Private Placement [Member] Other Other Other Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Table] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Table] Income Contract And Revenue Income, Other [Member] Contract And Revenue Income, Other Purchase of Convertible Senior Notes hedge Payments for Derivative Instrument, Financing Activities Potentially dilutive shares excluded from calculation due to anti-dilutive effect (in shares) Antidilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of operating segments Number of Operating Segments Proceeds from sale of short-term investments Proceeds from Sale of Short-Term Investments Entity Central Index Key Entity Central Index Key Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Accrued debt issuance costs Accrued Debt Issuance Costs Incurred But Not Yet Paid Accrued Debt Issuance Costs Incurred But Not Yet Paid Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Investment, Name [Axis] Investment, Name [Axis] Kyprolis Kyprolis [Member] Kyprolis Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Variable Rate [Domain] Variable Rate [Domain] Debt Instrument, Redemption, Period One Debt Instrument, Redemption, Period One [Member] Restricted Stock Awards Restricted stock Restricted Stock [Member] Accumulated other comprehensive income AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Assets Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Option Volatility Measurement Input, Option Volatility [Member] Previously Reported Previously Reported [Member] Statement [Line Items] Statement [Line Items] Total assets Assets Payout range (as a percent) Share-Based Compensation, Achievement Of Performance Criteria, Payout Range, Percent Share-Based Compensation, Achievement Of Performance Criteria, Payout Range, Percent Schedule of Fair-Value Options Awarded to Employees and Directors Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Interest expense Interest expense Interest Expense, Nonoperating Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax PEO PEO [Member] Other long-term liabilities Total other long-term liabilities Other Liabilities, Noncurrent Goodwill Goodwill Goodwill Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Number of positions in an unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Income from financial royalty assets Financial Royalty Assets [Member] Financial Royalty Assets Retained earnings Retained Earnings [Member] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Revolving Credit Facility Revolving Credit Facility [Member] Pelthos Series A convertible preferred shares Pelthos Common Shares And Series A convertible Preferred Shares [Member] Pelthos Common Shares And Series A convertible Preferred Shares Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Corporate notes/bonds Corporate Debt Securities [Member] Diluted net income (loss) per share (in USD per share) Earnings Per Share, Diluted Unrealized loss on available-for-sale investments, net of tax Unrealized gain (loss) on equity method investments Unrealized Gain (Loss) on Investments Litigation Case [Domain] Litigation Case [Domain] Zerion Pharma Zerion Pharma [Member] Zerion Pharma Intangible Asset, Finite-Lived Intangible Asset, Finite-Lived [Line Items] Measurement Input, Share Price Measurement Input, Share Price [Member] Frequency of cash payments to CVR holders Business Combination, Frequency Of Cash Payments To Contingent Value Rights Holders Business Combination, Frequency Of Cash Payments To Contingent Value Rights Holders XOMA Royalty Corporation XOMA Royalty Corporation [Member] XOMA Royalty Corporation Total revenues and income Total revenues and income Revenue from Contract with Customer, Excluding Assessed Tax Additional principal amount Line of Credit Facility, Remaining Borrowing Capacity Schedule of Equity Method Investments Equity Method Investments [Table Text Block] Stock repurchased during period, value Stock Repurchased During Period, Value Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Less: net increase in cash and cash equivalents classified within assets held for sale Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Discontinued Operation Purchases of short-term investments Payments to Acquire Short-Term Investments Cost of Captisol Cost, Direct Material Captisol Material Sales, Captisol [Member] Material Sales, Captisol After one year through five years Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost Number of CVR series Number Of Contingent Value Rights Series Number Of Contingent Value Rights Series Proceeds from Pelthos investors Proceeds from Investors, Financing Activities Proceeds from Investors, Financing Activities Sale of Stock [Axis] Sale of Stock [Axis] Non-operating income and expenses: Other Nonoperating Income (Expense) [Abstract] Fair value adjustments to partner program derivatives Fair value adjustments to partner program derivatives Derivative, Gain (Loss) on Derivative, Net Operating income (loss) Net income (loss) Operating Income (Loss) Qarziba QARZIBA [Member] QARZIBA Employee Stock Purchase Plan Employee Stock Purchase Plan [Abstract] Employee Stock Purchase Plan [Abstract] Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Corporate equity securities Equity Securities [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock issued (in shares) Common Stock, Shares, Issued Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Accounts receivable Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Additional ordinary shares (in shares) Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Deferred income taxes, net Deferred Income Tax Liabilities, Net Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Termination Date Trading Arrangement Termination Date Other Commitments [Axis] Other Commitments [Axis] Subsequent Events [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Pelthos Transaction Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other current liabilities Other Liabilities, Current Total current derivative assets Derivative Asset, Current Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Repayments of convertible debt Repayments of Convertible Debt Debt Instrument, Redemption Price(as a percent) Debt Instrument, Redemption Price, Percentage Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Total operating costs and expenses Operating Costs and Expenses Arrangement Duration Trading Arrangement Duration Arecor Limited Arecor Limited [Member] Arecor Limited Long-term portion of financial royalty assets, net Financial Royalty Assets, Non Current Financial Royalty Assets, Non Current Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Royalties owed to third parties Accrued Royalties Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Definite-lived intangible assets Intangible Asset, Finite-Lived, before Accumulated Amortization Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Pelthos loan receivable Pelthos Loan Receivable [Member] Pelthos Loan Receivable Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Total Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value Operating costs and expenses: Operating Costs and Expenses [Abstract] Intangible Asset, Finite-Lived, Class [Domain] Intangible Asset, Finite-Lived, Class [Domain] Trade name Trade Names [Member] Equity Award [Domain] Award Type [Domain] Fair Value Measurements Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] U.S. Government Agencies US Government Agencies Debt Securities [Member] Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Stock price trigger to classify convertible debt as current (as a percent) Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Business combination, recognized identifiable assets acquired and liabilities assumed, contract assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets Legal Entity [Axis] Legal Entity [Axis] Interest expense Interest Expense, Debt Equity Method Investments Equity Method Investments [Policy Text Block] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Professional fees Accrued Professional Fees, Current Purchases of derivatives Payments for Derivative Instrument, Investing Activities Non-NEOs Non-NEOs [Member] Cash payments for acquisition Payments to Acquire Businesses, Gross Investment owned, net assets, percentage Equity Method Investment, Ownership Percentage Hurdle One Hurdle One [Member] Hurdle One Xepi Xepi [Member] Xepi Accounts Receivable and Allowance for Credit Losses Credit Loss, Financial Instrument [Policy Text Block] Amended Credit Agreement Amended Credit Agreement [Member] Amended Credit Agreement Schedule of Equity of the Convertible Senior Notes Schedule of Debt [Table Text Block] Investment, Name [Domain] Investment, Name [Domain] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Schedule of Accounting for Share-Based Compensation Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Customer deposit Contract with Customer, Liability, Current Repurchase of common stock Repurchase of common stock Payments for Repurchase of Common Stock Risk Free Interest Rate Measurement Input, Risk Free Interest Rate [Member] Co-venturer Co-venturer [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Notes Payable, Current and Noncurrent [Abstract] Notes Payable, Current and Noncurrent [Abstract] Award Type [Axis] Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Retained earnings Retained Earnings (Accumulated Deficit) CECL adjustment to financial royalty assets Current And Expected Credit Loss Adjustment Current And Expected Credit Loss Adjustment Product and Service [Axis] Product and Service [Axis] Minimum consolidated EBITDA Debt Covenant, Minimum Consolidated EBITDA Debt Covenant, Minimum Consolidated EBITDA Pelthos Common Shares Equity Securities, FV-NI Threshold trading days Debt Instrument, Convertible, Threshold Trading Days Payments to acquire loan Payments to Acquire Loans Receivable Investment Holdings [Table] Investment Holdings [Table] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Estimated fair value Debt Securities, Available-for-Sale Convertible Senior Notes due 2031 Convertible Senior Notes due 2031 [Member] Convertible Senior Notes due 2031 Dividend yield (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate contractual interest expense Interest Expense, Debt, Excluding Amortization Debt Covenant Period [Domain] Debt Covenant Period [Domain] Debt Covenant Period [Domain] Derivative Contract [Domain] Derivative Contract [Domain] Pelthos Conversion Option Pelthos Conversion Option [Member] Pelthos Conversion Option Total liabilities and stockholders’ equity Liabilities and Equity Total goodwill and other identifiable intangible assets, net Intangible Asset, Including Goodwill, after Accumulated Amortization Stock Options Stock options Share-Based Payment Arrangement, Option [Member] Other Purchasers Other Purchasers [Member] Other Purchasers Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Related Party [Domain] Related and Nonrelated Parties [Domain] Research and Development Funding Research and Development Funding [Member] Research and Development Funding Tabular List, Table Tabular List [Table Text Block] Sale of stock, authorized offering amount Sale Of Stock, Authorized Offering Amount Sale Of Stock, Authorized Offering Amount Additional paid-in capital Additional Paid in Capital Convertible Senior Notes (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Income taxes receivable Income Taxes Receivable, Current Name Awards Close in Time to MNPI Disclosures, Individual Name Unrealized gain (loss) on hybrid instrument, net Unrealized Gain (Loss) on Hybrid Instrument, Net Ohtuvayre inventors Financial Ohtuvayre Inventors [Member] Financial Ohtuvayre Inventors Agenus Warrant And Castle Creek Warrant Agenus Warrant And Castle Creek Warrant [Member] Agenus Warrant And Castle Creek Warrant Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] 2031 Notes hedge and warrant transactions, net of tax Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt After one year through five years Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value Price per share Sale of Stock, Price Per Share Amended ESPP Amended ESPP [Member] Amended ESPP Property, Plant, and Equipment [Table] Property, Plant, and Equipment [Table] Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at June 30, 2026 and December 31, 2025 Preferred Stock, Value, Issued InvIOs investment InvIOs [Member] InvIOs Adjustment to Compensation: Adjustment to Compensation [Axis] Purchasers Purchasers [Member] Purchasers Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Payments to acquire productive assets Payments to Acquire Productive Assets Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activity Debt Covenant Initial Period Debt Covenant Initial Period [Member] Debt Covenant Initial Period Credit Facility [Axis] Credit Facility [Axis] Total assets Assets, Fair Value Disclosure Name Measure Name Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Debt Instrument [Line Items] Debt Instrument [Line Items] Additional paid in capital Additional Paid-in Capital [Member] Convertible Senior Notes due 2030 Convertible Senior Notes due 2030 [Member] Convertible Senior Notes due 2030 Name Trading Arrangement, Individual Name Series A Convertible Preferred Stock Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock Cash and cash equivalents Cash and Cash Equivalent Measurement Input, Expected Term Measurement Input, Expected Term [Member] Net increase (decrease) in cash, cash equivalents and restricted cash, including cash and cash equivalents classified within assets held for sale Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operation Company Selected Measure Amount Company Selected Measure Amount Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated [Table Text Block] Loss from change in fair value of equity-method investments and other investments Equity Securities, FV-NI, Unrealized Gain (Loss) Depreciation of fixed assets and amortization of intangible assets Depreciation, Depletion and Amortization Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Other Royalty Intangible, Other [Member] Royalty Intangible, Other Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Non-PEO NEO Non-PEO NEO [Member] Dilutive potential common shares: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Covenant minimum consolidated EBITDA Line Of Credit Facility, Covenant Minimum Consolidated EBITDA Line Of Credit Facility, Covenant Minimum Consolidated EBITDA Award Timing Method Award Timing Method [Text Block] Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Net income (loss) Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Gross carrying value Financial Royalty Assets, Gross Financial Royalty Assets, Gross Restatement Determination Date: Restatement Determination Date [Axis] US District Court for the Northern District of Ohio US District Court For The Northern District Of Ohio [Member] US District Court For The Northern District Of Ohio Outstanding options that are exercisable, weighted average exercise price (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Number of civil complaints filed against entity Loss Contingency, New Claims Filed, Number Initial Purchaser Warrants Initial Purchaser Warrants [Member] Initial Purchaser Warrants Revenues and income: Revenues [Abstract] Change in fair value Fair Value, Option, Changes in Fair Value, Gain (Loss) Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of Goodwill and Other Identifiable Intangible Assets Intangible Asset and Goodwill [Table Text Block] Schedule of Other Assets Schedule of Other Assets, Noncurrent [Table Text Block] Asset Acquisition [Table] Asset Acquisition [Table] Castle Creek Investment Castle Creek Investment [Member] Castle Creek Investment Statistical Measurement [Domain] Statistical Measurement [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Ownership percentage Equity Method Investment, Maximum Ownership Percentage Equity Method Investment, Maximum Ownership Percentage Share-based compensation expense Share-Based Payment Arrangement, Expense, after Tax Agenus Warrant Agenus Warrant [Member] Agenus Warrant Restricted Stock Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Annual revenue Royalty Income, Revenue Threshold Royalty Income, Revenue Threshold Common stock, $0.001 par value; 60,000 shares authorized; 19,920 and 19,774 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively Common Stock, Value, Issued Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Performance period for awards (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Line of Credit Line of Credit [Member] Restatement Determination Date Restatement Determination Date Inventory write-down Inventory Write-down Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Financial Royalty Assets, net Financial Royalty Assets [Policy Text Block] Financial Royalty Assets Settlement of related party debt Repayments of Related Party Debt Amendment Flag Amendment Flag Current liabilities: Liabilities, Current [Abstract] Payments under finance lease obligations Finance Lease, Principal Payments Gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gain (loss) from change in fair value of equity-method investments and other investments Gain (Loss) From Change In Fair Value Of Equity-Method Investments and Other Investments Gain (Loss) From Change In Fair Value Of Equity-Method Investments and Other Investments Schedule of Available-for-Sale Debt Securities Debt Securities, Available-for-Sale [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Convertible receivable, receivable value Convertible Receivable, Receivable Value Convertible Receivable, Receivable Value Deferred income taxes, net Increase (Decrease) in Deferred Income Taxes Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Payments to acquire equity securities, fv-ni Payments to Acquire Equity Securities, FV-NI Foreign currency translation adjustment, net of tax Foreign currency translation adjustment, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent PEO Total Compensation Amount PEO Total Compensation Amount Contracted royalty revenue Finance Agreement, Contracted Royalty Revenue Finance Agreement, Contracted Royalty Revenue Assets: Assets, Fair Value Disclosure [Abstract] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Shares used in basic per share calculation (in shares) Weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Loss Contingencies [Line Items] Loss Contingencies [Line Items] Receivable with imputed interest, face amount Receivable with Imputed Interest, Face Amount Asset acquisition, consideration transferred Asset Acquisition, Consideration Transferred Funding Allocation [Domain] Funding Allocation [Domain] Funding Allocation [Domain] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] RSUs vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Class of Stock [Axis] Class of Stock [Axis] Basis of Presentation and Principles of Consolidation Basis of Accounting, Policy [Policy Text Block] Non-cash income from financial royalty assets Non-cash Income From Financial Royalty Assets Non-cash Income From Financial Royalty Assets Receivable [Domain] Receivable [Domain] Less: accumulated amortization Intangible Asset, Finite-Lived, Accumulated Amortization Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Accounting Standards Updates, Recently Adopted and Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Net Income (Loss) Per Share Earnings Per Share, Policy [Policy Text Block] Litigation Case [Axis] Litigation Case [Axis] Accrued fixed asset purchases Capital Expenditures Incurred but Not yet Paid Deferred revenue Increase (Decrease) in Contract with Customer, Liability Amortization of debt issuance costs Amortization of Debt Issuance Costs Investment Transactions Asset Acquisition [Text Block] Preferred Class A Preferred Class A [Member] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Research and Development Funding Expense Research and Development Expense, Policy [Policy Text Block] Schedule of Other Investment Summary Investment Holdings [Table Text Block] Long-term portion of notes payable Long-Term Debt Exercise price (in USD per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Revenue from intangible royalty assets Intangible Royalty Assets [Member] Intangible Royalty Assets Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Unrecognized tax benefits Unrecognized Tax Benefits Stockholders' Equity Equity [Text Block] Security Exchange Name Security Exchange Name Change in estimated fair value of contingent liabilities Non Cash Change In Estimated Fair Value Of Contingent Value Rights Granted (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price AT220 AT220 [Member] AT220 Total liabilities Liabilities, Fair Value Disclosure Impairment of equity method investment Equity Method Investment, Other-than-Temporary Impairment Convertible receivable, embedded conversion value Convertible Receivable, Embedded Conversion Value Convertible Receivable, Embedded Conversion Value Accrued interest Interest Payable, Current Segment Information Segment Reporting, Policy [Policy Text Block] Statement of Comprehensive Income [Abstract] Name Outstanding Recovery, Individual Name Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Number of CVRs issued per acquiree share Business Combination, Number Of Contingent Value Rights Issued Per Acquiree Share Business Combination, Number Of Contingent Value Rights Issued Per Acquiree Share Warrants And Option Warrants And Option [Member] Warrants And Option Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Payments to acquire common stock and warrants Payments to Acquire Common Stock and Warrants Payments to Acquire Common Stock and Warrants Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Amortization of debt discount and issuance fees Amortization of Debt Issuance Costs and Discounts Contract revenue and income Contract Revenue And Other Income [Member] Contract Revenue And Other Income Supplemental schedule of non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] (Gain) loss on derivative instruments Unrealized Gain (Loss) on Derivatives Purchases of other investments Payments to Acquire Other Investments Principal amount of the 2031 and 2030 Notes outstanding Long-Term Debt, Gross Other long-term liabilities Other Sundry Liabilities, Noncurrent Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Agenus Warrant Warrant [Member] Shares used in diluted per share calculation (in shares) Shares used to compute diluted income (loss) per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Derivative Assets Derivatives, Policy [Policy Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Commercial paper Commercial Paper [Member] Long-term contingent liabilities Liability For Contingent Value Rights Basis of Presentation [Table] Basis of Presentation [Table] Basis of Presentation. Letters of credit outstanding Letters of Credit Outstanding, Amount Debt Securities, Available-for-sale Debt Securities, Available-for-Sale [Line Items] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date Hurdle [Domain] Hurdle [Domain] Hurdle [Domain] Nonvested at beginning of period (in USD per share) Nonvested at end of period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value All Executive Categories All Executive Categories [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] (Decrease) increase of mark-to-market adjustment of CVR liability Liabilities, Fair Value Adjustment Asset Acquisition [Domain] Asset Acquisition [Domain] Tangible asset impairment charges Tangible Asset Impairment Charges Hurdle [Axis] Hurdle [Axis] Hurdle Percentage of milestones (as a percent) Milestone Compensation Rate Milestone Compensation Rate Effective interest rate (percent) Receivable with Imputed Interest, Effective Yield (Interest Rate) Debt Covenant Subsequent Period Debt Covenant Subsequent Period [Member] Debt Covenant Subsequent Period CyDex CyDex [Member] CyDex Contract revenue Contract Revenue [Member] Contract Revenue Development and Licensing of Biopharmaceutical Assets Development And Licensing of Biopharmaceutical Assets [Member] Development And Licensing of Biopharmaceutical Assets Income tax receivable and payable Increase (Decrease) in Income Taxes Receivable Convertible senior notes, net Senior Notes, Noncurrent Schedule of Computation of Basic and Diluted Earnings per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Debt Disclosure [Abstract] 2031 Notes Option 2031 Notes Option [Member] 2031 Notes Option Minimum Minimum [Member] Investments, fair value Investments, Fair Value Disclosure Schedule of Revenue by Source Disaggregation of Revenue [Table Text Block] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Location, Statement of Income, Balance [Axis] Location, Statement of Income, Balance [Axis] (AT229) Financial Royalty AT292 Program [Member] AT292 Program Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Common stock authorized (in shares) Common Stock, Shares Authorized Sale of common stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Number of contingent value rights issued Number of Contingent Value Rights Issued Number of Contingent Value Rights Issued Exercise Price Award Exercise Price Authorized stock repurchase amount Share Repurchase Program, Authorized, Amount Subcontractor Accrued Subcontractor Expenses, Current Accrued Subcontractor Expenses, Current Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Warrant related to the 2030 Notes Warrant Related To The 2030 Notes [Member] Warrant Related To The 2030 Notes Acecor Warrants Acecor Warrants [Member] Acecor Warrants (AT220) Financial Royalty AT220 Program [Member] AT220 Program Unamortized debt discount and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity method investments Fair value on December 31, 2025 Fair value on June 30, 2026 Equity Method Investments Equity Component [Domain] Equity Component [Domain] Fair value adjustments to derivative assets Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Measurement Input Type [Domain] Measurement Input Type [Domain] Complete technology Patented Technology [Member] Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Share repurchase in connection with the 2031 Notes (Note 8) Share Repurchase in Connection with ProceedsnFrom Debt Issuance Share Repurchase in Connection with ProceedsnFrom Debt Issuance Adoption Date Trading Arrangement Adoption Date Inventory Inventory, Policy [Policy Text Block] Teriparatide injection Teriparatide Injection [Member] Teriparatide Injection Counterparty Name [Domain] Counterparty Name [Domain] Total non-operating income (expenses), net Nonoperating Income (Expense) Other Financial Royalty, Other [Member] Financial Royalty, Other Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Risk-free interest rate (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Number of CVRs issued from each CVR series Business Combination, Number Of Contingent Value Rights Issued From Each Contingent Value Right Series Business Combination, Number Of Contingent Value Rights Issued From Each Contingent Value Right Series Balance at beginning of period (in shares) Balance at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Interest income Interest Income, Operating Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Business Combination [Domain] Business Combination [Domain] Metabasis Therapeutics Metabasis Therapeutics [Member] Metabasis Therapeutics [Member] Commitment and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Current contingent liabilities Current Portion Of Liability For Contingent Value Rights Current portion of liability for contingent value rights. Weighted Average Weighted Average [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Accounts receivable, issuance cost Accounts Receivable, Issuance Cost Accounts Receivable, Issuance Cost Royalty income rate (as percent) Royalty Income Rate, Base Tier Royalty Income Rate, Base Tier Other Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Business Combination [Axis] Business Combination [Axis] Net cash provided by (used in) operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to CVR holders and other contingent payments Payments To Contingent Value Right Holders Payments To Contingent Value Right Holders Payments to acquire notes receivable Payments to Acquire Notes Receivable Income Statement [Abstract] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Filspari Filspari [Member] Filspari Gain (loss) from short-term investments Gain (Loss) on Investments Deferred income taxes, net Deferred Income Tax Assets, Net Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Investor Group Investor Group [Member] Investor Group Other Commitments [Domain] Other Commitments [Domain] City Area Code City Area Code 2030 Convertible Senior Notes Convertible Debt Securities [Member] Subsequent Events Subsequent Events [Text Block] Name Forgone Recovery, Individual Name Funding Allocation [Axis] Funding Allocation [Axis] Funding Allocation Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Entity [Domain] Entity [Domain] Preferred stock issued (in shares) Preferred Stock, Shares Issued Investments Investments [Roll Forward] Investments Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Gross proceeds from issuance of Convertible Senior Notes Proceeds from Convertible Debt Tolerance Therapeutics (Tzield®) Tolerance Therapeutics [Member] Tolerance Therapeutics Measurement Basis [Axis] Measurement Basis [Axis] Number of shares of common stock available (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period LeonaBio LeonaBio [Member] LeonaBio Fair value on December 31, 2025 Fair value on June 30, 2026 Investments Granted (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Domain] Subsequent Event Type [Domain] Income taxes payable Taxes Payable, Current Revision of Prior Period [Domain] Revision of Prior Period [Domain] Forfeited (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Debt discount and payment of debt issuance cost Payments of Debt Issuance Costs Ohtuvayre inventors Ohtuvayre Inventors [Member] Ohtuvayre Inventors Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Product royalty (as a percent) Product Royalty Percentage Product Royalty Percentage Liabilities: Liabilities, Fair Value Disclosure [Abstract] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Research and development Research and Development Expense Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Net carrying value Financial Royalty Assets, Net Financial Royalty Assets, Net Line of credit facility, interest rate (as a percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Financial Instruments [Domain] Financial Instruments [Domain] Derivative asset Derivative Asset Intangible Asset, Finite-Lived, Class [Axis] Intangible Asset, Finite-Lived, Class [Axis] Increase (decrease) in allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Underlying Securities Award Underlying Securities Amount Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Forfeited (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Preferred Stock Preferred Stock [Member] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Line Items] Inventory Increase (Decrease) in Inventories Amortization of intangibles Amortization of intangibles Cost, Amortization Short-term Investments Marketable Securities, Policy [Policy Text Block] Other current assets Other Assets, Current Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Schedule of Assets and Liabilities Measured at Fair Value Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Current Fiscal Year End Date Current Fiscal Year End Date Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Derivative [Line Items] Derivative [Line Items] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Share repurchase in connection with the 2031 Notes (in shares) Stock repurchased during period (in shares) Stock Repurchased During Period, Shares Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Within one year Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Castle Creek Warrant Castle Creek Warrant [Member] Castle Creek Warrant Schedule of Stock Option Plan Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Measure: Measure [Axis] Amortization of debt discount (premium) Amortization of Debt Discount (Premium) Warrant related to the 2031 Notes Warrant Related To The 2031 Notes [Member] Warrant Related To The 2031 Notes Equity Components [Axis] Equity Components [Axis] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Entity Interactive Data Current Entity Interactive Data Current Variable Rate [Axis] Variable Rate [Axis] Entity Small Business Entity Small Business Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Property, Plant, and Equipment Property, Plant, and Equipment [Line Items] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other assets Total other assets Other Assets, Noncurrent Document Type Document Type Metabasis Metabasis [Member] Metabasis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Proceeds from sale of derivatives Proceeds from Derivative Instrument, Investing Activities Contract revenue and income Contract Revenue And Income [Member] Contract Revenue And Income Proceeds from financial royalty assets Proceeds From Financial Royalty Assets Proceeds From Financial Royalty Assets Subsequent Event Subsequent Event [Line Items] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Warrants term (in years) Warrants and Rights Outstanding, Term Commitments and contingencies Commitments and Contingencies Schedule of Other Long Term Liabilities Other Noncurrent Liabilities [Table Text Block] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Warrant measurement input (as a percent) Warrants and Rights Outstanding, Measurement Input Executive Category: Executive Category [Axis] Receivable Type [Axis] Receivable Type [Axis] Schedule of Restricted Stock Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Counterparty Name [Axis] Counterparty Name [Axis] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost [Abstract] Pelthos Convertible Notes Pelthos Convertible Notes [Member] Pelthos Convertible Notes Inventory Inventory Inventory, Net Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Equity issuance cost Equity Issuance Cost Equity Issuance Cost PEO Name PEO Name Additional royalties receivable under sales-based milestones Additional Royalties Receivable Under Sales-based Milestones Additional Royalties Receivable Under Sales-based Milestones Taxes paid Income Tax Paid, before Refund Received Other Segment Reporting, Other Segment Item, Amount Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Options exercised (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Revenue and Income Revenue [Policy Text Block] Other Other Accrued Liabilities, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Base Rate Base Rate [Member] Rylaze Rylaze [Member] Rylaze Proceeds from maturity of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Options, Restricted Stock Awards And 2030 Convertible Senior Notes Stock Options, Restricted Stock Awards, Performance Stock Awards And Notes [Member] Stock Options, Restricted Stock Awards, Performance Stock Awards And 2030 Notes Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Schedule of Short-Term Investments Schedule Of Short-Term investments [Table Text Block] Schedule Of Short-Term investments Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument [Axis] Debt Instrument [Axis] Subsequent Event [Table] Subsequent Event [Table] Share-based compensation Share-based compensation Share-Based Payment Arrangement, Noncash Expense Basic net income (loss) per share (in USD per share) Earnings Per Share, Basic Measurement Input Type [Axis] Measurement Input Type [Axis] Total current assets Assets, Current Insider Trading Arrangements [Line Items] At-the Market Equity Offering At-The Market Equity Offering [Member] At-The Market Equity Offering Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Unrealized loss on available-for-sale securities, net of tax Unrealized loss on available-for-sale securities, net of tax Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Expected volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Ordinary Shares Ordinary Shares [Member] Ordinary Shares Investment, Type [Extensible Enumeration] Investment, Type [Extensible Enumeration] Equity Awards Adjustments Equity Awards Adjustments [Member] Cost method investment in Zerion Cost Method Investment in Zerion [Member] Cost Method Investment in Zerion Asset Acquisition Asset Acquisition [Line Items] Plan Name [Axis] Plan Name [Axis] Pelthos Pelthos Technologies [Member] Pelthos Technologies Derivative liability, measurement input Derivative Liability, Measurement Input Other expense items, net Other Expense Items, Net Other Expense Items, Net Other non-operating expense, net Other Nonoperating Income (Expense) Short-Term Investments Short-Term Investments [Member] Convertible Senior Notes due 2031 - Initial Purchase Option Convertible Senior Notes due 2031 - Initial Purchase Option [Member] Convertible Senior Notes due 2031 - Initial Purchase Option Acquire investments Payments to Acquire Investments Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period General and administrative General and Administrative Expense Preferred stock authorized (in shares) Preferred Stock, Shares Authorized Share Repurchase Program [Axis] Share Repurchase Program [Axis] Class of Stock [Domain] Class of Stock [Domain] Statement of Cash Flows [Abstract] Payments for repurchase of warrants Payments for Repurchase of Warrants Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Income Tax Income Tax Disclosure [Text Block] Zerion Zerion [Member] Zerion Zelsuvmi Zelsuvmi [Member] Zelsuvmi Accounts payable Accounts Payable, Current Asset acquisition, deferred consideration, number of installments Asset Acquisition, Deferred Consideration, Number Of Installments Asset Acquisition, Deferred Consideration, Number Of Installments Leaona Bio Series B Warrants Leaona Bio Series B Warrants [Member] Leaona Bio Series B Warrants Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] (Gain) loss from short-term investments Gain (Loss) on Short-term Investments Gain (Loss) on Short-term Investments Entity Filer Category Entity Filer Category Short-term investments Short-Term Investments Impairment loss of financial royalty assets Impairment Loss On Financial Royalty Assets Impairment Loss On Financial Royalty Assets Contingent liabilities Contingent Liabilities [Member] Contingent Liabilities April 2023 Repurchase Agreement April 2023 Repurchase Agreement [Member] April 2023 Repurchase Agreement Revision of Prior Period [Axis] Revision of Prior Period [Axis] Within one year Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost 2031 Convertible Senior Notes 2031 Convertible Senior Notes [Member] 2031 Convertible Senior Notes Castle Creek Warrant Castle Creek Warrants [Member] Castle Creek Warrants Other segment items: Segment Reporting, Reconciliation of Other Item by Segment to Consolidated [Abstract] Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Business combination common stock (in USD per share) Business Combination, Price Per Share Current assets: Assets, Current [Abstract] Derivative liabilities Derivative Liability Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Entity Address, Address Line One Entity Address, Address Line One Addition of right-of-use assets and lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability RSUs vested (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Income tax (expense) benefit Income Tax Expense (Benefit) Convertible Notes Convertible Notes Payable [Member] Capvaxive Capvaxive [Member] Capvaxive Deferred tax liability Business Combination, Recognized Liability Assumed, Deferred Tax Liability Statement [Table] Statement [Table] Proceeds from issuance of warrants Proceeds from Issuance of Warrants Net proceeds from stock option exercises and ESPP Proceeds from Stock Options Exercised Interest income Investment Income, Interest Accrued Liabilities Accrued Liabilities [Abstract] Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block]